Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations

被引：0
|
作者：
Wu, Y. -L. [1 ]
Opdam, F. [2 ]
Yamamoto, N. [3 ]
Yoshida, T. [3 ]
Heymach, J. [4 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Natl Canc Ctr, Chuo Ku, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12D.06
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [41] Plasma EGFR and Her2 levels in non-small cell lung cancer patients treated with gefitinib
    Kasahara, K.
    Tamori, S.
    Sakai, A.
    Tambo, Y.
    Araya, T.
    Sone, T.
    Kimura, H.
    Fujimura, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] HER2 Mutations in Non-Small-Cell Lung Cancer Can Be Continually Targeted
    Kelly, Ronan J.
    Carter, Corey A.
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3318 - 3319
  • [43] HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
    Suzuki, Mikiko
    Shiraishi, Kouya
    Yoshida, Akihiko
    Shirnada, Yoko
    Suzuki, Kenji
    Asamura, Hisao
    Furuta, Koh
    Kohno, Takashi
    Tsuta, Koji
    LUNG CANCER, 2015, 87 (01) : 14 - 22
  • [44] Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type
    Berz, D.
    Heymach, J.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y.
    Mueller, A. M.
    Schroeter, L.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S127 - S127
  • [45] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Brazel, Danielle
    Kroening, Gianna
    Nagasaka, Misako
    BIODRUGS, 2022, 36 (06) : 717 - 729
  • [46] Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer
    Shen, Hongli
    Du, Guoli
    Liu, Zhonghua
    Bao, Jianling
    Yu, Qin
    Jia, Chunli
    Liang, Xuelin
    Shan, Li
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (12): : 22300 - 22309
  • [47] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Danielle Brazel
    Gianna Kroening
    Misako Nagasaka
    BioDrugs, 2022, 36 : 717 - 729
  • [48] HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
    Christina Garrido-Castro, Ana
    Felip, Enriqueta
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (02) : 122 - 127
  • [49] Management of HER2 alterations in non-small cell lung cancer - The past, present, and future
    Nuetzinger, Jorn
    Lee, Jii Bum
    Low, Jia Li
    Chia, Puey Ling
    Wijaya, Silvana Talisa
    Cho, Byoung Chul
    Lim, Sun Min
    Soo, Ross A.
    LUNG CANCER, 2023, 186
  • [50] Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
    Siegel, Franziska
    Karsli-Uzunbas, Gizem
    Kotynkova, Kristyna
    McVeigh, Quinn
    Siegel, Stephan
    Korr, Daniel
    Schulze, Volker
    Berger, Markus
    Beckmann, Georg
    Cherniack, Andrew
    Meyerson, Matthew
    Greulich, Heidi
    CANCER RESEARCH, 2023, 83 (07)
12345